Real world treatment patterns following the initiation of proprotein convertase subtilisin/kexin type 9 antibody inhibitors among adults in the United States, 2015-2019
Publication
, Conference
Wiener, C; Levintow, SN; Orroth, KK; Gill, K; Mullard, A; McGrath, LJ; Brookhart, MA
Published in: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
2020
Duke Scholars
Published In
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
EISSN
1099-1557
ISSN
1053-8569
Publication Date
2020
Volume
29
Start / End Page
55 / 56
Related Subject Headings
- Pharmacology & Pharmacy
- 4202 Epidemiology
- 3214 Pharmacology and pharmaceutical sciences
- 1117 Public Health and Health Services
- 1115 Pharmacology and Pharmaceutical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Wiener, C., Levintow, S. N., Orroth, K. K., Gill, K., Mullard, A., McGrath, L. J., & Brookhart, M. A. (2020). Real world treatment patterns following the initiation of proprotein convertase subtilisin/kexin type 9 antibody inhibitors among adults in the United States, 2015-2019. In PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (Vol. 29, pp. 55–56).
Wiener, Catie, Sara N. Levintow, Kate K. Orroth, Karminder Gill, Andrew Mullard, Leah J. McGrath, and M Alan Brookhart. “Real world treatment patterns following the initiation of proprotein convertase subtilisin/kexin type 9 antibody inhibitors among adults in the United States, 2015-2019.” In PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 29:55–56, 2020.
Wiener C, Levintow SN, Orroth KK, Gill K, Mullard A, McGrath LJ, et al. Real world treatment patterns following the initiation of proprotein convertase subtilisin/kexin type 9 antibody inhibitors among adults in the United States, 2015-2019. In: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2020. p. 55–6.
Wiener, Catie, et al. “Real world treatment patterns following the initiation of proprotein convertase subtilisin/kexin type 9 antibody inhibitors among adults in the United States, 2015-2019.” PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, vol. 29, 2020, pp. 55–56.
Wiener C, Levintow SN, Orroth KK, Gill K, Mullard A, McGrath LJ, Brookhart MA. Real world treatment patterns following the initiation of proprotein convertase subtilisin/kexin type 9 antibody inhibitors among adults in the United States, 2015-2019. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2020. p. 55–56.
Published In
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
EISSN
1099-1557
ISSN
1053-8569
Publication Date
2020
Volume
29
Start / End Page
55 / 56
Related Subject Headings
- Pharmacology & Pharmacy
- 4202 Epidemiology
- 3214 Pharmacology and pharmaceutical sciences
- 1117 Public Health and Health Services
- 1115 Pharmacology and Pharmaceutical Sciences